entertainment -WSS

entertainment

author：entertainment 2025-09-30 01:02:23 - browse：7946

A judge ruled that Welsh Carson won't have to face antitrust allegations about its anesthesiology practice. Adobe

Welsh, Carson, Anderson & Stowe has wiggled out of the grasp of the Federal Trade Commission, but the private equity firm’s anesthesia company, U.S. Anesthesia Partners, still must face the agency’s antitrust case, a judge ruled last week.

The FTC alleged last year that the anesthesiology network monopolized markets in Texas to drive up prices, but took the unusual step of attaching Welsh Carson as a defendant with USAP. Dismissing Welsh Carson from the case was a victory for the private equity firm and, more broadly, other firms worried that the Biden administration would try to hold them responsible for anything their portfolio companies do.

But the allegations against USAP didn’t disappear, which will keep up scrutiny on companies that have made a push to acquire numerous physician groups.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily market-moving biopharma analysis — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Vivek Ramaswamy made waves in the debate, much as in biotech

WSS

PBMs are inflating the cost of generic drugs. They must be reined in

Astellas still sees hope in its gene therapy after four deaths

Vivek Ramaswamy made waves in the debate, much as in biotech

FDA advisory panel to debate high blood pressure devices

Abortion policy in the spotlight at Republican debate

World's first CRISPR

explore

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily market-moving biopharma analysis — by subscribing to STAT+.

entertainment

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Can U.S. cancer drug shortages be fixed?

Duchenne breakthrough therapy leaves behind pioneering families

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

Bright Health sells Medicare Advantage business to Molina

Anthos stroke drug appears safer than common blood thinner

Drug repurposing or repositioning? The language matters

Astellas still sees hope in its gene therapy after four deaths

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Former Pear Therapeutics executives start new VC firm

knowledge

Wegovy, Zepbound and weight loss drugs that preserve muscle

Wegovy improves function in certain heart failure patients

Abortion policy in the spotlight at Republican debate

Former Pear Therapeutics executives start new VC firm

Study: Spinal cord stimulation helps patients with paralysis walk again

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

leisure time

explore

hotspot

hotspot